bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell… Read more
bioAffinity Technologies, Inc. (BIAF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.279x
Based on the latest financial reports, bioAffinity Technologies, Inc. (BIAF) has a cash flow conversion efficiency ratio of -0.279x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.48 Million) by net assets ($8.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
bioAffinity Technologies, Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how bioAffinity Technologies, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
bioAffinity Technologies, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of bioAffinity Technologies, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zuleika Gold Ltd
AU:ZAG
|
-0.049x |
|
Snail, Inc. Class A Common Stock
NASDAQ:SNAL
|
-0.311x |
|
Michael Anthony Holdings Inc
PINK:MAJJ
|
-0.053x |
|
Global Star Acquisition Inc.
NASDAQ:GLSTU
|
-0.200x |
|
Ulima Nitra PT
JK:UNIQ
|
0.040x |
|
XPLUS SA ZY -01
F:75R
|
N/A |
|
BIOFISH HOLDING AS NK 1
F:9R2
|
N/A |
|
Sical Logistics Limited
NSE:SICALLOG
|
N/A |
Annual Cash Flow Conversion Efficiency for bioAffinity Technologies, Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of bioAffinity Technologies, Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.60 Million | $-7.26 Million | -2.792x | -124.51% |
| 2023-12-31 | $4.86 Million | $-6.04 Million | -1.244x | -237.35% |
| 2022-12-31 | $11.04 Million | $-4.07 Million | -0.369x | -384.08% |
| 2021-12-31 | $-15.79 Million | $-2.05 Million | 0.130x | -11.41% |
| 2020-12-31 | $-15.07 Million | $-2.21 Million | 0.146x | -76.26% |
| 2019-12-31 | $-4.04 Million | $-2.49 Million | 0.617x | -- |